Hemogenomics Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 30-05-2024
- Paid Up Capital ₹ 2.23 Cr
as on 30-05-2024
- Company Age 22 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 40.00 Cr
as on 30-05-2024
- Revenue 44.71%
(FY 2023)
- Profit 131.56%
(FY 2023)
- Ebitda 169.06%
(FY 2023)
- Net Worth 12.82%
(FY 2023)
- Total Assets -4.07%
(FY 2023)
About Hemogenomics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 2.23 Cr.
The company currently has active open charges totaling ₹40.00 Cr.
Anurag Bagaria, William Rutter, and Sumit Bagaria serve as directors at the Company.
- CIN/LLPIN
U73100KA2002PTC030032
- Company No.
030032
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jan 2002
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Hemogenomics Private Limited offer?
Hemogenomics Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Corona Test Kit.
Who are the key members and board of directors at Hemogenomics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumit Bagaria  | Managing Director | 18-Jan-2011 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
William Rutter  | Director | 25-Nov-2002 | Current |
| Anurag Bagaria | Director | 08-Mar-2010 | Current |
Financial Performance and Corporate Structure Insights of Hemogenomics.
Hemogenomics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 44.71% increase. The company also saw a substantial improvement in profitability, with a 131.56% increase in profit. The company's net worth Soared by an impressive increase of 12.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hemogenomics?
In 2023, Hemogenomics had a promoter holding of 65.02% and a public holding of 34.99%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Citi Bank N.A. Creation Date: 02 Mar 2016 | ₹5.00 Cr | Open |
Citi Bank N.A. Creation Date: 11 Jan 2012 | ₹35.00 Cr | Open |
How Many Employees Work at Hemogenomics?
Hemogenomics has a workforce of 99 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hemogenomics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hemogenomics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
